# GRIN Therapeutics

**Canonical:** https://apis.io/providers/grin-therapeutics/  
**Website:** https://grintherapeutics.com/  
**APIs profiled:** 8

GRIN Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders caused by NMDA receptor dysfunction. It is an affiliate of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, and traces its founding to Dr. Pierandrea Muglia's attendance at the 2019 CFERV Conference on GRIN Variants at Emory University. Its lead investigational asset is radiprodil, an orally bioavailable selective negative allosteric modulator of the GluN2B subunit of the NMDA receptor, designed to fine-tune dysregulated receptor activity rather than fully block the channel. Radiprodil is in development for GRIN-related neurodevelopmental disorder (GRIN-NDD) arising from gain-of-function variants in GRIN1, GRIN2A, GRIN2B and GRIN2D, and for tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. The clinical programme comprises the completed Phase 1b/2a Honeycomb trial, the enrolling global Phase 3 Beeline registrational trial, the Phase 1b/2a Astroscape trial in TSC and FCD type II, and a GRIN-NDD natural history study; radiprodil carries FDA Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations and EMA PRIME and Orphan Drug designations. In May 2025 GRIN Therapeutics entered an exclusive collaboration with Angelini Pharma to develop and commercialise radiprodil outside North America. GRIN Therapeutics runs no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable surface reachable without credentials is the WordPress REST content API behind grintherapeutics.com, catalogued here.

## Kin Score — 28.2 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 28.2).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 54.3 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 16.8 |
| Commercial Clarity | 10.5 |

Regulatory layer — **Health**: 26.3 (matched via tags).

## Agent readiness — 33.1 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | partial |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (8)

- **GRIN Therapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **GRIN Therapeutics Media API** — Media library (174 attachments at harvest time).
- **GRIN Therapeutics Oembed API** — oEmbed 1.0 provider endpoint for grintherapeutics.com URLs.
- **GRIN Therapeutics Pages API** — Corporate and clinical-programme pages (10 published at harvest time).
- **GRIN Therapeutics Posts API** — Blog/news post collection. Registered and reachable, but empty (X-WP-Total 0) — the News page is authored as a WPBakery page, not as posts.
- **GRIN Therapeutics Search API** — Cross-content search across published objects.
- **GRIN Therapeutics Taxonomy API** — Categories and tags. Registered by WordPress core; every term reports count 0 on this deployment.
- **GRIN Therapeutics Users API** — Public author records.

## Security (2)

- **Grin Therapeutics Authentication** — none/http · 3 schemes
- **Grin Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, biotechnology, pharmaceuticals, neuroscience, rare-disease, precision-medicine, clinical-trials, pediatrics, epilepsy, life-sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/grin-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.